8 Triptans Alternatives for Chronic Migraine Sufferers

This article is for informational purposes only and is not medical advice. Consult a qualified healthcare provider before making changes to your migraine treatment plan.

Triptans have been a go-to acute migraine treatment for decades. But for the nearly 15% of adults in the United States who live with migraine, triptans are not always the right fit. Some people cannot take them because of cardiovascular conditions. Others find the relief incomplete or short-lived. And for those with chronic migraine, defined as 15 or more headache days per month for at least three months, relying on triptans alone can lead to medication overuse headache, a cycle that makes the problem worse.

The good news: the last several years have brought a wave of new options. From targeted medications that work through entirely different pathways to behavioral programs that retrain the nervous system, there are now more evidence-based alternatives than ever. This listicle covers eight of them, organized from newer pharmacological options to device-based and behavioral approaches, so you can discuss what might work with your care team.

Key Takeaways

• Chronic migraine affects roughly 2% of the global population, and triptans are contraindicated in patients with cardiovascular conditions like coronary artery disease and cerebrovascular disease.
• CGRP-targeting medications (monoclonal antibodies and gepants) are now recommended as first-line preventive options by the American Headache Society.
• OnabotulinumtoxinA (Botox) and neuromodulation devices offer non-oral alternatives with evidence supporting their use in adults with chronic migraine.
• Behavioral approaches, including CBT and biofeedback, reduce migraine-related disability and may address underlying nervous system patterns that keep chronic migraine going.
• Lin Health's brain-first behavioral program is based on neuroplastic pain research, delivered by trained recovery coaches, and covered by major insurers in CO, TX, FL, CA, and NY.

Behavioral and Brain-First Alternatives

Chronic migraine is not just a medication problem. Research increasingly shows that how the nervous system processes and amplifies pain signals plays a major role in migraine chronification. Behavioral approaches work at that level.

1. Brain-First Behavioral Programs

The newest category of migraine management addresses something the other alternatives do not: the nervous system's learned patterns that keep chronic migraine going. This approach, sometimes called neuroplastic pain treatment, targets the brain's pain-processing circuits directly through structured behavioral retraining.

How it works

Chronic migraine can involve central sensitization, where the nervous system becomes increasingly reactive to normal stimuli. Over time, the brain's pain alarm can get stuck in a heightened state, firing even when there is no acute threat. Brain-first programs use a combination of modalities, including CBT, ACT (Acceptance and Commitment Therapy), somatic tracking, and emotional awareness techniques, to retrain these neural pathways.

A 2024 systematic review and meta-analysis of 21 RCTs found that ACT produces medium pain-related effect sizes for pain interference, depression, and functional impairment in adults with chronic pain, with effects growing stronger at the three-month follow-up. A 2023 pilot trial in women with migraine showed ACT is feasible for migraine patients, with slightly larger reductions in migraine days compared to usual care.

What makes this approach different

Unlike medications that block a single molecule (CGRP, serotonin) or devices that stimulate a single nerve, brain-first programs work on the broader pattern. They address the fear-avoidance cycles, emotional triggers, and cognitive loops that research links to chronification and central sensitization.

The key advantage for chronic migraine sufferers is that behavioral retraining has no medication interactions, no cardiovascular contraindications, and no risk of overuse headache. It can be used alone or alongside any of the other alternatives on this list.

Who this may be a good fit for

Adults with chronic migraine who have cycled through multiple medications without lasting relief, those whose migraines seem connected to stress, emotions, or fear of attacks, and anyone looking for a long-term strategy that goes beyond symptom management. This approach is based on findings from neuroplastic pain research and is available through structured programs like Lin Health.

2. Cognitive Behavioral Therapy for Migraine

CBT is the most-studied behavioral treatment for chronic pain conditions, including migraine. It does not replace medication; it works alongside it, targeting the thoughts, emotions, and behaviors that can amplify migraine frequency and disability.

How it works

Migraine-specific CBT helps patients identify and change patterns that worsen migraine, including catastrophizing, fear-avoidance behaviors, stress reactivity, and sleep disruption. Sessions typically run weekly for 8 to 12 weeks, delivered in person or virtually.

What the evidence shows

Multiple randomized controlled trials support CBT for migraine. A 2023 moderator analysis found that migraine-specific CBT reduces headache-related disability, particularly for patients with higher baseline disability. A 2024 RCT demonstrated that CBT combined with treatment for comorbid insomnia improved chronic migraine outcomes in adults with co-occurring chronic insomnia, with 81.5% achieving clinical improvement at 18 months.

The broader evidence base from a Cochrane review of CBT for chronic pain confirms small beneficial effects on pain, disability, and distress that are maintained at follow-up.

Who this may be a good fit for

Adults with chronic migraine who notice that stress, sleep problems, or anxiety patterns trigger or worsen their attacks. CBT may be especially useful for patients who have tried multiple medications without adequate relief and want to address contributing behavioral factors.

3. Biofeedback and Relaxation Training

Biofeedback teaches patients to monitor and control physiological responses, such as muscle tension, heart rate, and skin temperature, that relate to migraine onset. Relaxation training, including progressive muscle relaxation and diaphragmatic breathing, is often combined with biofeedback.

How it works

During biofeedback sessions, sensors placed on the skin display real-time physiological data. Patients learn to reduce muscle tension (EMG biofeedback), warm their hands by increasing blood flow (thermal biofeedback), or regulate heart rate variability (HRV biofeedback). Over time, these skills become automatic and can be practiced without equipment.

What the evidence shows

A comprehensive meta-analysis of 94 studies found medium-to-large effect sizes for biofeedback in adult migraine patients, with treatment effects remaining stable at an average follow-up of 14 months. Improvements were seen across headache frequency, self-efficacy, anxiety, depression, and medication use.

When combined with relaxation training and cognitive stress coping techniques, biofeedback cuts headache frequency and medication use compared to monitoring alone.

Who this may be a good fit for

Adults and adolescents who want a non-medication approach with strong evidence, those who notice physical tension patterns before or during migraine attacks, and patients interested in building long-term self-regulation skills.

Pharmacological Alternatives

These options target different biological pathways than triptans and may work for patients who cannot take triptans or who need better preventive coverage.

4. CGRP Monoclonal Antibodies (Preventive Injections)

CGRP (calcitonin gene-related peptide) plays a central role in migraine attacks. Unlike triptans, which constrict blood vessels and act on serotonin receptors, CGRP monoclonal antibodies block the CGRP molecule or its receptor directly, without cardiovascular effects.

How they work

Four FDA-approved monoclonal antibodies target the CGRP pathway: erenumab, fremanezumab, galcanezumab, and eptinezumab. They are delivered as monthly or quarterly injections (or IV infusions for eptinezumab) and are designed for migraine prevention, not acute relief.

What the evidence shows

A 2024 Bayesian network meta-analysis of 10 clinical trials found that galcanezumab 120 mg was most effective for prevention, with approximately 2.7 fewer migraine days per month compared to placebo in adults with chronic migraine. Fremanezumab showed the highest responder rate (OR: 2.9 for 50% reduction), and eptinezumab had the most favorable safety profile.

The American Headache Society's 2024 consensus statement now recommends CGRP as first-line preventive treatment, without requiring prior failure of older drug classes.

Who this may be a good fit for

Adults with chronic migraine who cannot tolerate triptans, have cardiovascular risk factors, or have not responded well to older preventive medications like topiramate or beta-blockers. These are prescription medications requiring a clinician's evaluation.

5. Gepants (Oral CGRP Blockers)

Gepants are small-molecule CGRP receptor antagonists. They can be taken as pills, making them a more accessible option for people who prefer not to inject.

How they work

Three gepants are FDA-approved: ubrogepant and rimegepant for acute migraine treatment, and atogepant for prevention. Rimegepant is also approved for preventive use. They block the CGRP receptor at the cellular level, which interrupts the migraine signaling cascade without the vasoconstrictive effects that make triptans risky for some patients.

What the evidence shows

The PROGRESS phase 3 trial tested atogepant specifically in adults with chronic migraine. Participants taking 30 mg twice daily experienced 7.5 fewer migraine days per month (compared to 5.1 in the placebo group), and the 60 mg once-daily dose reduced monthly migraine days by 6.9. Both doses were well tolerated across the 755-person trial.

Atogepant is described as the first oral migraine preventive specifically approved for chronic migraine, a distinction that matters for the roughly 2% of adults whose migraine frequency meets chronic thresholds.

Who this may be a good fit for

Adults with chronic or episodic migraine who want an oral option, particularly those with cardiovascular conditions that rule out triptans. Atogepant may also help patients dealing with acute medication overuse.

6. Ditans (Lasmiditan)

Ditans represent a newer class of acute migraine treatment. Unlike triptans, they do not constrict blood vessels, which removes the cardiovascular contraindication entirely.

How they work

Lasmiditan is the only FDA-approved ditan. It activates the 5-HT1F serotonin receptor (triptans target 5-HT1B/1D), which reduces migraine pain signals without affecting blood vessels. This makes it an option for patients with heart disease, uncontrolled hypertension, or stroke history.

What the evidence shows

A 2024 systematic review and network meta-analysis found that lasmiditan (100 mg and 200 mg) has faster two-hour relief compared to ubrogepant and zavegepant. Real-world data from a 2025 study of 108 patients showed a 50% efficacy rate with the 50 mg dose, though side effects, particularly dizziness and drowsiness, were common. Patients should not drive for at least eight hours after taking lasmiditan.

Who this may be a good fit for

Adults who need acute migraine relief but have cardiovascular conditions that make triptans unsafe. The driving restriction and sedation profile mean it may work better for people who can take it at home rather than at work.

7. OnabotulinumtoxinA (Botox)

Botox has been FDA-approved for chronic migraine prevention since 2010 and remains one of the most studied options for this population.

How they work

A healthcare provider injects small amounts of onabotulinumtoxinA into 31 specific sites across the head and neck, following the PREEMPT protocol. The injections are repeated every 12 weeks. The mechanism is thought to involve blocking pain neurotransmitter release at nerve endings, which reduces the frequency and intensity of migraine attacks over time.

What the evidence shows

Long-term real-world data is strong. A 2025 longitudinal study following 579 patients for up to 11 years found that over 90% achieved relief, with monthly headache days dropping from an average of 22.7 to 5.5 after 60 months of treatment. A separate 5-year retrospective study confirmed a favorable long-term safety profile in adults with chronic migraine.

Who this may be a good fit for

Adults with chronic migraine (15+ headache days per month) who have not responded adequately to oral preventive medications. Botox requires in-office visits every three months but avoids the daily pill burden of oral preventives.

Device-Based Alternatives

For patients looking to reduce medication use entirely, FDA-cleared neuromodulation devices offer a non-pharmacological acute and preventive option.

8. Neuromodulation Devices

Several FDA-cleared devices use electrical or magnetic stimulation to interrupt migraine pain signals. They carry few systemic side effects since they act locally on nerves rather than circulating through the body.

How they work

The main categories include:

• External trigeminal nerve stimulation (e-TNS): Cefaly, worn on the forehead, stimulates the trigeminal nerve. Cleared for both acute and preventive use.
• Non-invasive vagus nerve stimulation (nVNS): gammaCore Sapphire, held against the neck, stimulates the vagus nerve. Cleared for acute and preventive treatment in people aged 12 and older.
• Single-pulse transcranial magnetic stimulation (sTMS): SAVI Dual (formerly SpringTMS), held against the back of the head, delivers magnetic pulses to the occipital cortex.
• Remote electrical neuromodulation (REN): Nerivio, worn on the upper arm, uses conditioned pain modulation.

What the evidence shows

The International Headache Society published evidence-based guidelines in 2025 after reviewing 15 studies. The panel issued recommendations for four devices, including Cefaly, gammaCore Sapphire, SAVI Dual, and Nerivio, for acute and/or preventive migraine treatment. Evidence quality ranged from very low to moderate, and the panel noted that more large-scale randomized trials are needed.

Cefaly has the most robust preventive data. In 2024, the FDA cleared a rechargeable version for daily preventive use.

Who this may be a good fit for

Adults and adolescents (12+) who want to reduce medication use, those with medication overuse headache, or patients who prefer a drug-free approach alongside other treatments. Devices can be combined with pharmacological or behavioral approaches.

How Lin Health Helps with Chronic Migraine

Lin Health's program is built on the brain-first principles described above. The approach is based on findings from research on PRT, CBT, ACT, and emotional awareness and expression therapy (EAET), applied specifically to chronic migraine and other persistent pain conditions.

Here is what the program looks like:

• Trained recovery coaches guide you through weekly live sessions, working on the specific thought patterns, emotional responses, and behaviors that feed your migraine cycle.
• Structured app-based modules designed by pain specialists provide learning and practice materials between coaching sessions.
• Multiple behavioral modalities including somatic tracking, graded exposure, imaginal exposure for migraines, and cognitive reframing are tailored to each patient's needs.
• Insurance covered in high-coverage states including Colorado, Texas, Florida, California, and New York, with additional coverage expanding. Most patients pay zero out of pocket.
• Short wait times with same-day callbacks for insurance eligibility checks.

Unlike general-purpose therapy, Lin Health's coaches are specialized in persistent symptoms, not broad mental health concerns. And unlike self-guided apps, you work with a real person who adjusts the program as you progress.

If you have tried triptans, preventive medications, or other acute treatments and still live with frequent migraines, a brain-first behavioral approach may be worth exploring. Lin Health is covered by most major insurance plans, and the initial eligibility check takes minutes. Check your eligibility now.

FAQ

What is the main reason people look for triptans alternatives? 

The most common reasons include cardiovascular conditions that make triptans unsafe, incomplete relief from migraine attacks, side effects like chest tightness or fatigue, and medication overuse headache from frequent triptan use. Newer options target different pathways without these limitations.

Can I use a behavioral approach alongside migraine medication? 

Yes. Behavioral treatments like CBT, biofeedback, and brain-first programs are designed to complement medication, not replace it. Many headache specialists recommend combining preventive medication with behavioral migraine management for the strongest outcomes.

Are CGRP medications safe for people with heart disease? 

CGRP monoclonal antibodies and gepants do not constrict blood vessels, which removes the main cardiovascular concern associated with triptans. The AHS 2024 consensus supports their use as first-line preventive treatment regardless of cardiovascular status. Discuss specific risks with your prescribing clinician.

How long does it take for behavioral migraine treatments to work? 

Most structured programs run 8 to 12 weeks, with measurable improvements in migraine frequency and disability often appearing within the first month. Effects tend to strengthen over time as skills become habitual, unlike medications that stop working when discontinued.

Does insurance cover behavioral migraine treatment? 

Coverage varies by plan and provider. Lin Health is covered by major insurers in CO, TX, FL, CA, and NY, with most patients paying zero out of pocket. General CBT and biofeedback may also be covered under behavioral health benefits.

What is the difference between episodic and chronic migraine? 

Episodic migraine involves fewer than 15 headache days per month. Chronic migraine means 15 or more headache days per month for at least three months, with at least eight of those days meeting full migraine criteria. About 3% of people with episodic migraine progress to chronic migraine each year.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment for migraine or chronic pain.